InVivoMAb anti-Eastern equine encephalitis virus E2 protein

Catalog #BE0433

$164.00 - $4,280.00

Choose an Option...
  • 100 mg - $4,280.00
  • 50 mg - $3,024.00
  • 25 mg - $2,009.00
  • 5 mg - $600.00
  • 1 mg - $164.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Details

The EEEV-3 monoclonal antibody reacts with the B domain of the E2 glycoprotein on the eastern equine encephalitis virus (EEEV). In humans and horses, EEEV is transmitted primarily through the bite of the swamp mosquito Culiseta melanura (i.e., black-tailed mosquito). Infected mosquitoes transmit the EEEV to birds as well, and uninfected mosquitoes acquire the EEEV infection through feeding on infected birds. Human EEEV infection incidences are low, but the mortality rate can be up to 70%, and the survivors end up with significant brain damage. Structurally, the EEEV is an enveloped virus with single-stranded positive sense RNA, and the mature virion displays spikes that are made of E2-E1 heterodimers. The E2 glycoprotein binds to some host cell receptors, and it is suggested to be responsible for viral entry and endocytosis. In experimental studies, antibodies against epitopes on the E2 protein (e.g., EEEV-3) are used to elucidate the molecular mechanism of EEEV infections. The EEEV-3 monoclonal antibody is specific for EEEV’s E2 glycoprotein (B domain), and it does not bind other related viruses such as the Western equine encephalitis virus (WEEV) and the Venezuelan equine encephalitis virus (VEEV). Cryo-EM structure analysis and alanine-scanning mutagenesis studies demonstrated that the Fab fragments of the EEEV-3 monoclonal antibody interact exclusively with an epitope localized to residues 180–182 on the B domain of the EEEV E2 glycoprotein. In vitro experiments have shown that the EEEV-3 monoclonal antibody exhibits a modest inhibition of viral attachment to the plasma membrane of the cells. Post-attachment neutralization assays showed the in vitro inhibitory activity of the EEEV-3 monoclonal antibody against SINV-EEEV infection when the antibody was added after the virus was bound to cells. In the FFWO assay, the EEEV-3 monoclonal antibody was added after viral attachment to Vero cells, and it was found that the antibody significantly blocks the virus plasma membrane fusion. FRNT assays involving the infection of Vero cells with EEEV particles that were pre-incubated in vitro with the EEEV-3 monoclonal antibody or its Fab fragments demonstrated that the bivalent mouse IgG monoclonal antibodies efficiently inhibit infection while the Fab fragments does not. The in vivo efficacy of the EEEV-3 monoclonal antibody was evaluated in CD-1 mice, which were inoculated with the highly pathogenic EEEV strain FL93-939. A single 100-μg i.p. injection of the EEEV-3 monoclonal antibody one day before or after subcutaneous or aerosol inoculation of EEEV (lethal doses) provided significant protection against viral infection.


Isotype Mouse IgG2c, κ
Recommended Isotype Control(s) InVivoMAb mouse IgG2c isotype control, anti-dengue virus
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Immunogen SINV-EEEV
Reported Applications in vivo protection against EEEV
in vitro neutralization of EEEV
Flow cytometry
Plasma membrane fusion-from-without (FFWO)
Focus reduction neutralization tests (FRNT)
Biolayer Interferometry (BLI)
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <2EU/mg (<0.002EU/μg)
Determined by LAL gel clotting assay
Purity >95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from cell culture supernatant in an animal-free facility
Purification Protein A
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.